Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
about
The role of adenosine signaling in sickle cell therapeuticsHow I use hydroxyurea to treat young patients with sickle cell anemia.Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.Update on the use of hydroxyurea therapy in sickle cell diseaseHydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell programPharmacotherapy in sickle cell disease--state of the art and future prospectsExamining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.Parental and other factors associated with hydroxyurea use for pediatric sickle cell diseaseHydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell diseaseA systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell diseaseHydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.How does catalase release nitric oxide? A computational structure-activity relationship study.HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.
P2860
Q27010098-F5348E4E-828E-4A27-901F-7B8BBBD02AA3Q33985120-FAA416E1-EB14-4D6D-9BF6-BF9AEEE73488Q34026647-2363F937-44B4-4B2C-8362-5209DCBB8568Q34737460-283947DC-1777-453D-BD73-BAD4DB61BA4FQ34964869-BB75C3DD-D8BE-49C8-B8BE-5E95D97A8902Q35220342-61C6FF1A-F256-457B-B402-2454579AB423Q35599915-F2DCA846-5168-480E-AFD5-7795939DCD3FQ35754065-7F09A8BF-04C4-448D-988F-69A94CFAF316Q35843842-C086E2D2-D121-4A79-8DC3-08E608A04341Q36275688-3CF68176-EE2E-4D58-BC58-BA12AC00D267Q36763705-6B478819-07E6-4D94-A16A-5FA4C9C0CE1EQ36777717-EC1F1344-F26F-4E06-9933-6FDA5244BF67Q36792555-22DE9FF7-B5D6-48B5-95BE-92B2C3458C84Q37223344-E8ED93BC-B657-4D8A-8798-380859B43F92Q37244000-8F6BF810-AD21-45FE-8D91-6B5AEDBC7404Q39340660-33D1B0E0-9169-4789-8565-A0896B7B9CE5Q52639727-C2CC6DA5-E368-47F3-8939-F11DD416343EQ55513319-0AF1A3A2-A516-4643-8881-C37829867BE0
P2860
Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@en
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@nl
type
label
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@en
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@nl
prefLabel
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@en
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@nl
P2093
P1476
Provider barriers to hydroxyur ...... isease Adult Provider Network.
@en
P2093
Carlton Haywood
Cynthia Rand
Kathryn L Hassell
Sophie Lanzkron
P304
P577
2008-08-01T00:00:00Z